In a press release published today, SanBio Inc. announced that 12 people have successfully enrolled for its Phase 1/2a clinical trial of their SB623 stem cell product. The clinical trial is conducted in the facilities of Stanford University and the University of Pittsburghand. The main purpose of the study is to test the safety (and partially the efficacy) of SB623 in ischemic stroke patients. Six more patients are expected to be enrolled.
SB623 is an allogenic cell therapy product that among others also contains mesenchymal stem cells derived from healthy adults. Several studies on animal models (mice) have shown that it can efficiently restore neural damage induced by strokes, spinal cord injuries and Parkinson's disease. According to SanBio, the therapy may also have potential applications in the treatment of patients presenting with Huntington's disease or Amyotrophic Lateral Sclerosis.
As mentioned before, the company will accept 6 more patients that meet the following prerequisites:
- The ischemic stroke occurred in the past 3 years
- Prenest with arm and/or leg weakness
- Are 18 to 75 years old
- No more than 1 stroke incidences
- No history of seizures
The participants will be examined and tested for two years for motor, sensory and cognitive abilities. Any costs related to the study (e.g. for transportation) will be covered by SanBio exclusively.
For more info click here
- SanBio is company focusing on the development of regenerative cell therapies for various neurological disorders including: stroke, spinal cord injury, Parkinson's disease, Multiple sclerosis.